1. Home
  2. MMC vs VRTX Comparison

MMC vs VRTX Comparison

Compare MMC & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MMC
  • VRTX
  • Stock Information
  • Founded
  • MMC 1871
  • VRTX 1989
  • Country
  • MMC United States
  • VRTX United States
  • Employees
  • MMC N/A
  • VRTX N/A
  • Industry
  • MMC Specialty Insurers
  • VRTX EDP Services
  • Sector
  • MMC Finance
  • VRTX Technology
  • Exchange
  • MMC Nasdaq
  • VRTX Nasdaq
  • Market Cap
  • MMC 111.7B
  • VRTX 115.6B
  • IPO Year
  • MMC N/A
  • VRTX 1991
  • Fundamental
  • Price
  • MMC $233.63
  • VRTX $442.05
  • Analyst Decision
  • MMC Hold
  • VRTX Buy
  • Analyst Count
  • MMC 13
  • VRTX 26
  • Target Price
  • MMC $239.85
  • VRTX $512.54
  • AVG Volume (30 Days)
  • MMC 1.8M
  • VRTX 2.2M
  • Earning Date
  • MMC 07-17-2025
  • VRTX 05-05-2025
  • Dividend Yield
  • MMC 1.40%
  • VRTX N/A
  • EPS Growth
  • MMC 3.44
  • VRTX N/A
  • EPS
  • MMC 8.15
  • VRTX N/A
  • Revenue
  • MMC $25,046,000,000.00
  • VRTX $11,099,700,000.00
  • Revenue This Year
  • MMC $11.29
  • VRTX $10.36
  • Revenue Next Year
  • MMC $5.67
  • VRTX $10.61
  • P/E Ratio
  • MMC $28.68
  • VRTX N/A
  • Revenue Growth
  • MMC 7.56
  • VRTX 8.98
  • 52 Week Low
  • MMC $201.84
  • VRTX $377.85
  • 52 Week High
  • MMC $248.00
  • VRTX $519.88
  • Technical
  • Relative Strength Index (RSI)
  • MMC 59.14
  • VRTX 43.63
  • Support Level
  • MMC $226.02
  • VRTX $427.43
  • Resistance Level
  • MMC $231.90
  • VRTX $451.64
  • Average True Range (ATR)
  • MMC 3.95
  • VRTX 10.29
  • MACD
  • MMC 0.66
  • VRTX 2.22
  • Stochastic Oscillator
  • MMC 94.62
  • VRTX 72.63

About MMC Marsh & McLennan Companies Inc.

Marsh McLennan is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: